请输入您要查询的百科知识：

　

词条 Sarcoidosis
释义

  1. Signs and symptoms

     Respiratory tract  Skin  Heart  Eye  Nervous system  Endocrine and exocrine  Gastrointestinal and genitourinary  Blood  Bone, joints, and muscles 

  2. Cause

     Genetics  Infectious agents  Autoimmune 

  3. Pathophysiology

  4. Diagnosis

     Classification 

  5. Treatment

     Antimetabolites  Immunosuppressants  Specific organ treatments  Symptoms 

  6. Prognosis

  7. Epidemiology

  8. History

     Etymology 

  9. Society and culture

  10. Pregnancy

  11. References

  12. External links

{{Hatnote|Not to be confused with sarcoma}}{{Infobox medical condition (new)
| name = Sarcoidosis
| synonyms = Sarcoïdosis, sarcoid, Besnier-Boeck-Schaumann disease[1]
| image = Chest X-ray of sarcoidosis nodules.png
| caption = Chest X-ray showing the typical nodularity of sarcoidosis, predominantly in the bases of the lungs.
| field = Rheumatology
| pronounce = sar-koy-DO-sis
| symptoms = Depends on the organ involved[2]
Lungs: wheezing, cough, shortness of breath, chest pain[3]
Skin: lumps, ulcers, discolored skin[3]
Children: weight loss, bone pain, feeling tired[3]
| complications =
| onset = 20–50 year old women[6]
| duration = Few years to long term[2][8]
| causes = Unknown[2]
| risks = Family history[6]
| diagnosis = Based on symptoms and tissue biopsy[11]
| differential = Tuberculosis, lymphoma, infectious mononucleosis, pulmonary eosinophilia[2]
| prevention =
| treatment = Ibuprofen, prednisone, methotrexate[13][14]
| medication =
| prognosis = Mortality 1–7%[8]
| frequency = 1.9 million with interstitial lung disease (2015)[16]
| deaths = 122,000 with interstitial lung disease (2015)[17]
}}Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomas.[2] The disease usually begins in the lungs, skin, or lymph nodes.[2] Less commonly affected are the eyes, liver, heart, and brain.[2] Any organ, however, can be affected.[2] The signs and symptoms depend on the organ involved.[2] Often, no, or only mild, symptoms are seen.[2] When it affects the lungs, wheezing, coughing, shortness of breath, or chest pain may occur.[3] Some may have Löfgren syndrome with fever, large lymph nodes, arthritis, and a rash known as erythema nodosum.[2]

The cause of sarcoidosis is unknown.[4] Some believe it may be due to an immune reaction to a trigger such as an infection or chemicals in those who are genetically predisposed.[5][6] Those with affected family members are at greater risk.[6] Diagnosis is partly based on signs and symptoms, which may be supported by biopsy.[11] Findings that make it likely include large lymph nodes at the root of the lung on both sides, high blood calcium with a normal parathyroid hormone level, or elevated levels of angiotensin converting enzyme in the blood.[11] The diagnosis should only be made after excluding other possible causes of similar symptoms such as tuberculosis.[7]

Sarcoidosis may resolve without any treatment within a few years.[4][8] However, some people may have long-term or severe disease.[8] Some symptoms may be improved with the use of anti-inflammatory drugs such as ibuprofen.[8] In cases where the condition causes significant health problems, steroids such as prednisone are indicated.[14] Medications such as methotrexate, chloroquine, or azathioprine may occasionally be used in an effort to decrease the side effects of steroids.[9] The risk of death is 1-7%.[10] The chance of the disease returning in someone who has had it previously is less than 5%.[4]

In 2015, pulmonary sarcoidosis and interstitial lung disease affected 1.9 million people globally and they resulted in 122,000 deaths.[11][12] It is most common in Scandinavians, but occurs in all parts of the world.[43] In the United States risk is greater among black as opposed to white people.[13] It usually begins between the ages of 20 and 50.[6] It occurs more often in women than men.[14] Sarcoidosis was first described in 1877 by the English doctor Jonathan Hutchinson as a nonpainful skin disease.[15]

Signs and symptoms

Sarcoidosis is a systemic inflammatory disease that can affect any organ, although it can be asymptomatic and is discovered by accident in about 5% of cases.[17] Common symptoms, which tend to be vague, include fatigue (unrelieved by sleep; occurs in 66% of cases), lack of energy, weight loss, joint aches and pains (which occur in about 70% of cases),[50] arthritis (14–38% of persons), dry eyes, swelling of the knees, blurry vision, shortness of breath, a dry, hacking cough, or skin lesions.[18][19][53][20] Less commonly, people may cough up blood.[18] The cutaneous symptoms vary, and range from rashes and noduli (small bumps) to erythema nodosum, granuloma annulare, or lupus pernio. Sarcoidosis and cancer may mimic one another, making the distinction difficult.[21]

The combination of erythema nodosum, bilateral hilar lymphadenopathy, and joint pain is called Löfgren syndrome, which has a relatively good prognosis.[18] This form of the disease occurs significantly more often in Scandinavian patients than in those of non-Scandinavian origin.[58]

Respiratory tract

Localization to the lungs is by far the most common manifestation of sarcoidosis.[22] At least 90% of affected persons experience lung involvement.[60] Overall, about 50% develop permanent pulmonary abnormalities, and 5 to 15% have progressive fibrosis of the lung parenchyma. Sarcoidosis of the lung is primarily an interstitial lung disease in which the inflammatory process involves the alveoli, small bronchi, and small blood vessels.[23] In acute and subacute cases, physical examination usually reveals dry crackles.[60] At least 5% of persons suffer pulmonary arterial hypertension.[60][24] The upper respiratory tract (including the larynx, pharynx, and sinuses) may be affected, which occurs in between 5 and 10% of cases.[65]

The four stages of pulmonary involvement are based on radiological stage of the disease, which is helpful in prognosis:[25]

  • Stage I: bilateral hilar lymphadenopathy (BHL) alone
  • Stage II: BHL with pulmonary infiltrates
  • Stage III: pulmonary infiltrates without BHL
  • Stage IV: fibrosis

Use of the Scadding scale only provides general information regarding the prognosis of the pulmonary disease over time. Caution is recommended, as it only shows a general relation with physiological markers of the disease and the variation is such that it has limited applicability in individual assessments, including treatment decisions.[5]

Skin

{{main|Skin manifestations of sarcoidosis}}

Sarcoidosis involves the skin in between 9 and 37% of persons and is more common in African Americans than in European Americans.[60] The skin is the second-most commonly affected organ after the lungs.[69] The most common lesions are erythema nodosum, plaques, maculopapular eruptions, subcutaneous nodules, and lupus pernio.[26] Treatment is not required, since the lesions usually resolve spontaneously in 2–4 weeks. Although it may be disfiguring, cutaneous sarcoidosis rarely causes major problems.[27][28][29] Sarcoidosis of the scalp presents with diffuse or patchy hair loss.[30][31]

Heart

The frequency of cardiac involvement varies and is significantly influenced by race; in Japan, more than 25% of persons with sarcoidosis have symptomatic cardiac involvement, whereas in the US and Europe, only about 5% of cases present with cardiac involvement.[27] Autopsy studies in the US have revealed a frequency of cardiac involvement of about 20–30%, whereas autopsy studies in Japan have shown a frequency of 60%.[53] The presentation of cardiac sarcoidosis can range from asymptomatic conduction abnormalities to fatal ventricular arrhythmia.[32][33] Conduction abnormalities are the most common cardiac manifestations of sarcoidosis in humans and can include complete heart block.[34] Second to conduction abnormalities, in frequency, are ventricular arrhythmias, which occurs in about 23% of persons with cardiac involvement.[34] Sudden cardiac death, either due to ventricular arrhythmias or complete heart block is a rare complication of cardiac sarcoidosis.[35][36] Cardiac sarcoidosis can cause fibrosis, granuloma formation, or the accumulation of fluid in the interstitium of the heart, or a combination of the former two.[37][38]

Eye

Eye involvement occurs in about 10–90% of cases.[53] Manifestations in the eye include uveitis, uveoparotitis, and retinal inflammation, which may result in loss of visual acuity or blindness.[39] The most common ophthalmologic manifestation of sarcoidosis is uveitis.[53][40][41] The combination of anterior uveitis, parotitis, VII cranial nerve paralysis and fever is called uveoparotid fever or Heerfordt syndrome ({{ICD10|D|86|8|d|80}}). Development of scleral nodule associated with sarcoidosis has been observed.[42]

Nervous system

{{main|Neurosarcoidosis}}

Any of the components of the nervous system can be involved.[43] Sarcoidosis affecting the nervous system is known as neurosarcoidosis.[43] Cranial nerves are most commonly affected, accounting for about 5–30% of neurosarcoidosis cases, and peripheral facial nerve palsy, often bilateral, is the most common neurological manifestation of sarcoidosis.[43][44][96] It occurs suddenly and is usually transient. The central nervous system involvement is present in 10–25% of sarcoidosis cases.[45] Other common manifestations of neurosarcoidosis include optic nerve dysfunction, papilledema, palate dysfunction, neuroendocrine changes, hearing abnormalities, hypothalamic and pituitary abnormalities, chronic meningitis, and peripheral neuropathy.[27] Myelopathy, that is spinal cord involvement, occurs in about 16–43% of neurosarcoidosis cases and is often associated with the poorest prognosis of the neurosarcoidosis subtypes.[43] Whereas facial nerve palsies and acute meningitis due to sarcoidosis tend to have the most favourable prognosis,[43] another common finding in sarcoidosis with neurological involvement is autonomic or sensory small-fiber neuropathy.[46][47] Neuroendocrine sarcoidosis accounts for about 5–10% of neurosarcoidosis cases and can lead to diabetes insipidus, changes in menstrual cycle and hypothalamic dysfunction.[43][48] The latter can lead to changes in body temperature, mood, and prolactin (see the endocrine and exocrine section for details).[43]

Endocrine and exocrine

Prolactin is frequently increased in sarcoidosis, between 3 and 32% of cases have hyperprolactinemia[49] this frequently leads to amenorrhea, galactorrhea, or nonpuerperal mastitis in women. It also frequently causes an increase in 1,25-dihydroxy vitamin D, the active metabolite of vitamin D, which is usually hydroxylated within the kidney, but in sarcoidosis patients, hydroxylation of vitamin D can occur outside the kidneys, namely inside the immune cells found in the granulomas the condition produces. 1,25-dihydroxy vitamin D is the main cause for hypercalcemia in sarcoidosis and overproduced by sarcoid granulomata. Gamma-interferon produced by activated lymphocytes and macrophages plays a major role in the synthesis of 1 alpha, 25(OH)2D3.[50] Hypercalciuria (excessive secretion of calcium in one's urine) and hypercalcemia (an excessively high amount of calcium in the blood) are seen in <10% of individuals and likely results from the increased 1,25-dihydroxy vitamin D production.[51]

Thyroid dysfunction is seen in 4.2–4.6% of cases.[52][53]

Parotid enlargement occurs in about 5–10% of persons.[50] Bilateral involvement is the rule. The gland is usually not tender, but firm and smooth. Dry mouth can occur; other exocrine glands are affected only rarely.[27] The eyes, their glands, or the parotid glands are affected in 20–50% of cases.[113]

Gastrointestinal and genitourinary

Symptomatic gastrointestinal (GI) involvement occurs in less than 1% of persons (if one excludes the liver), and most commonly the stomach is affected, although the small or large intestine may also be affected in a small portion of cases.[50][54] Studies at autopsy have revealed GI involvement in less than 10% of people.[48] These cases would likely mimic Crohn's disease, which is a more commonly intestine-affecting granulomatous disease.[50] About 1–3% of people have evidence of pancreatic involvement at autopsy.[48] Symptomatic kidney involvement occurs in just 0.7% of cases, although evidence of kidney involvement at autopsy has been reported in up to 22% of people and occurs exclusively in cases of chronic disease.[50][55][48] Symptomatic kidney involvement is usually nephrocalcinosis, although granulomatous interstitial nephritis that presents with reduced creatinine clearance and little proteinuria is a close second.[50][48] Less commonly, the epididymis, testicles, prostate, ovaries, fallopian tubes, uterus, or the vulva may be affected, the latter may cause vulva itchiness.[55][56][57] Testicular involvement has been reported in about 5% of people at autopsy.[48][57] In males, sarcoidosis may lead to infertility.[57]

Around 70% of people have granulomas in their livers, although only in about 20–30% of cases, liver function test anomalies reflecting this fact are seen.[18][27] About 5–15% of persons exhibit hepatomegaly.[55] Only 5–30% of cases of liver involvement are symptomatic.[58] Usually, these changes reflect a cholestatic pattern and include raised levels of alkaline phosphatase (which is the most common liver function test anomaly seen in persons with sarcoidosis), while bilirubin and aminotransferases are only mildly elevated. Jaundice is rare.[50][27]

Blood

Abnormal blood tests are frequent, accounting for over 50% of cases, but are not diagnostic.[27][45] Lymphopenia is the most common blood anomaly in sarcoidosis.[27] Anemia occurs in about 20% of people with sarcoidosis.[27] Leukopenia is less common and occurs in even fewer persons but is rarely severe.[27] Thrombocytopenia and hemolytic anemia are fairly rare.[50] In the absence of splenomegaly, leukopenia may reflect bone marrow involvement, but the most common mechanism is a redistribution of blood T cells to sites of disease.[59] Other nonspecific findings include monocytosis, occurring in the majority of sarcoidosis cases,[60] increased hepatic enzymes or alkaline phosphatase. People with sarcoidosis often have immunologic anomalies like allergies to test antigens such as Candida or purified protein derivative.[113] Polyclonal hypergammaglobulinemia is also a fairly common immunologic anomaly seen in sarcoidosis.[61]

Lymphadenopathy (swollen glands) is common in sarcoidosis and occurs in 15% of cases.[20] Intrathoracic nodes are enlarged in 75 to 90% of all people; usually this involves the hilar nodes, but the paratracheal nodes are commonly involved. Peripheral lymphadenopathy is very common, particularly involving the cervical (the most common head and neck manifestation of the disease), axillary, epitrochlear, and inguinal nodes.[62] Approximately 75% of cases show microscopic involvement of the spleen, although only in about 5–10% of cases does splenomegaly appear.[50][61]

Bone, joints, and muscles

Sarcoidosis can be involved with the joints, bones, and muscles. This causes a wide variety of musculoskeletal complaints that act through different mechanisms.[63]

About 5–15% of cases affect the bones, joints, or muscles.[45]

Arthritic syndromes can be categorized as acute or chronic.[63]

Sarcoidosis patients suffering acute arthritis often also have bilateral hilar lymphadenopathy and erythema nodosum. These three associated syndromes often occur together in Löfgren syndrome.[63] The arthritis symptoms of Löfgren syndrome occur most frequently in the ankles, followed by the knees, wrists, elbows, and metacarpophalangeal joints.[63] Usually, true arthritis is not present, but instead, periarthritis appears as a swelling in the soft tissue around the joints that can be seen by ultrasonographic methods.[63]

These joint symptoms tend to precede or occur at the same time as erythema nodosum develops.[63] Even when erythema nodosum is absent, it is believed that the combination of hilar lymphadenopathy and ankle periarthritis can be considered as a variant of Löfgren syndrome.[63]

Enthesitis also occurs in about one-third of patients with acute sarcoid arthritis, mainly affecting the Achilles tendon and heels.[63] Soft-tissue swelling of the ankles can be prominent, and biopsy of this soft tissue reveals no granulomas, but does show panniculitis similar to erythema nodosum.[63]

Chronic sarcoid arthritis usually occurs in the setting of more diffuse organ involvement.[63] The ankles, knees, wrists, elbows, and hands may all be affected in the chronic form and often this presents itself in a polyarticular pattern.[63] Dactylitis similar to that seen in psoriatic arthritis, that is associated with pain, swelling, overlying skin erythema, and underlying bony changes may also occur.[63] Development of Jaccoud arthropathy (a nonerosive deformity) is very rarely seen.[63]

Bone involvement in sarcoidosis has been reported in 1–13% of cases.[48] The most frequent sites of involvement are the hands and feet, whereas the spine is less commonly affected.[63] Half of the patients with bony lesions experience pain and stiffness, whereas the other half remain asymptomatic.[63]

Periostitis is rarely seen in sarcoidosis and has been found to present itself at the femoral bone.[64][65]

Cause

The exact cause of sarcoidosis is not known.[4] The current working hypothesis is, in genetically susceptible individuals, sarcoidosis is caused through alteration to the immune response after exposure to an environmental, occupational, or infectious agent.[66] Some cases may be caused by treatment with TNF inhibitors like etanercept.[67]

Genetics

The heritability of sarcoidosis varies according to ethnicity. About 20% of African Americans with sarcoidosis have a family member with the condition, whereas the same figure for European Americans is about 5%. Additionally, in African Americans, who seem to experience more severe and chronic disease, siblings and parents of sarcoidosis cases have about a 2.5-fold increased risk for developing the disease.[68] In Swedish individuals heritability was found to be 39%.[69] In this group, if a first-degree family member was affected, a person has a four-fold greater risk of being affected.[69]

Investigations of genetic susceptibility yielded many candidate genes, but only few were confirmed by further investigations and no reliable genetic markers are known. Currently, the most interesting candidate gene is BTNL2; several HLA-DR risk alleles are also being investigated.[70][71] In persistent sarcoidosis, the HLA haplotype HLA-B7-DR15 is either cooperating in disease or another gene between these two loci is associated. In nonpersistent disease, a strong genetic association exists with HLA DR3-DQ2.[72][73] Cardiac sarcoid has been connected to TNFA variants.[74]

Infectious agents

Several infectious agents appear to be significantly associated with sarcoidosis, but none of the known associations is specific enough to suggest a direct causative role.[75] The major implicated infectious agents include: mycobacteria, fungi, borrelia, and rickettsia.[181] A meta-analysis investigating the role of mycobacteria in sarcoidosis found it was present in 26.4% of cases, but they also detected a possible publication bias, so the results need further confirmation.[76][77] Mycobacterium tuberculosis catalase-peroxidase has been identified as a possible antigen catalyst of sarcoidosis.[78] The disease has also been reported by transmission via organ transplants.[79]

Autoimmune

Association of autoimmune disorders has been frequently observed. The exact mechanism of this relation is not known, but some evidence supports the hypothesis that this is a consequence of Th1 lymphokine prevalence.[52][80] Tests of delayed cutaneous hypersensitivity have been used to measure progression.[81]

Pathophysiology

Granulomatous inflammation is characterized primarily by accumulation of macrophages and activated T-lymphocytes, with increased production of key inflammatory mediators, TNF, IFN-γ, IL-2, IL-8, IL-10, IL-12, IL-18, IL-23 and TGF-β, indicative of a Th1-mediated immune response.[82][83]

Sarcoidosis has paradoxical effects on inflammatory processes; it is characterized by increased macrophage and CD4 helper T-cell activation, resulting in accelerated inflammation, but immune response to antigen challenges such as tuberculin is suppressed. This paradoxic state of simultaneous hyper- and hypoactivity is suggestive of a state of anergy. The anergy may also be responsible for the increased risk of infections and cancer.

The regulatory T-lymphocytes in the periphery of sarcoid granulomas appear to suppress IL-2 secretion, which is hypothesized to cause the state of anergy by preventing antigen-specific memory responses.[84]

Schaumann bodies seen in sarcoidosis are calcium and protein inclusions inside of Langhans giant cells as part of a granuloma.

While TNF is widely believed to play an important role in the formation of granulomas (which is further supported by the finding that in animal models of mycobacterial granuloma formation inhibition of either TNF or IFN-γ production inhibits granuloma formation), sarcoidosis can and does still develop in persons being treated with TNF antagonists like etanercept.[85]

B cells also likely play a role in the pathophysiology of sarcoidosis.[68] Serum levels of soluble HLA class I antigens and ACE are higher in persons with sarcoidosis.[68] Likewise the ratio of CD4/CD8 T cells in bronchoalveolar lavage is usually higher in persons with pulmonary sarcoidosis (usually >3.5), although it can be normal or even abnormally low in some cases.[68] Serum ACE levels have been found to usually correlate with total granuloma load.[82]

Cases of sarcoidosis have also been reported as part of the immune reconstitution syndrome of HIV, that is, when people receive treatment for HIV their immune system rebounds and the result is that it starts to attack the antigens of opportunistic infections caught prior to said rebound and the resulting immune response starts to damage healthy tissue.[83]

Diagnosis

Diagnosis of sarcoidosis is a matter of exclusion, as there is no specific test for the condition. To exclude sarcoidosis in a case presenting with pulmonary symptoms might involve a chest radiograph, CT scan of chest, PET scan, CT-guided biopsy, mediastinoscopy, open lung biopsy, bronchoscopy with biopsy, endobronchial ultrasound, and endoscopic ultrasound with fine-needle aspiration of mediastinal lymph nodes (EBUS FNA). Tissue from biopsy of lymph nodes is subjected to both flow cytometry to rule out cancer and special stains (acid fast bacilli stain and Gömöri methenamine silver stain) to rule out microorganisms and fungi.[86][87][5][88]

Serum markers of sarcoidosis, include: serum amyloid A, soluble interleukin-2 receptor, lysozyme, angiotensin converting enzyme, and the glycoprotein KL-6.[202] Angiotensin-converting enzyme blood levels are used in the monitoring of sarcoidosis.[89] A bronchoalveolar lavage can show an elevated (of at least 3.5) CD4/CD8 T cell ratio, which is indicative (but not proof) of pulmonary sarcoidosis.[68] In at least one study the induced sputum ratio of CD4/CD8 and level of TNF was correlated to those in the lavage fluid.[89] A sarcoidosis-like lung disease called granulomatous–lymphocytic interstitial lung disease can be seen in patients with common variable immunodeficiency (CVID) and therefore serum antibody levels should be measured to exclude CVID.

Differential diagnosis includes metastatic disease, lymphoma, septic emboli, rheumatoid nodules, granulomatosis with polyangiitis, varicella infection, tuberculosis, and atypical infections, such as Mycobacterium avium complex, cytomegalovirus, and cryptococcus.[90] Sarcoidosis is confused most commonly with neoplastic diseases, such as lymphoma, or with disorders characterized also by a mononuclear cell granulomatous inflammatory process, such as the mycobacterial and fungal disorders.[27]

Chest radiograph changes are divided into four stages:[91]

  1. bihilar lymphadenopathy
  2. bihilar lymphadenopathy and reticulonodular infiltrates
  3. bilateral pulmonary infiltrates
  4. fibrocystic sarcoidosis typically with upward hilar retraction, cystic and bullous changes

Although people with stage 1 radiographs tend to have the acute or subacute, reversible form of the disease, those with stages 2 and 3 often have the chronic, progressive disease; these patterns do not represent consecutive "stages" of sarcoidosis. Thus, except for epidemiologic purposes, this categorization is mostly of historic interest.[27]

In sarcoidosis presenting in the Caucasian population, hilar adenopathy and erythema nodosum are the most common initial symptoms. In this population, a biopsy of the gastrocnemius muscle is a useful tool in correctly diagnosing the person. The presence of a noncaseating epithelioid granuloma in a gastrocnemius specimen is definitive evidence of sarcoidosis, as other tuberculoid and fungal diseases extremely rarely present histologically in this muscle.[92]

Classification

Sarcoidosis may be divided into the following types:[30]

{{div col|colwidth=18em}}
  • Annular sarcoidosis
  • Erythrodermic sarcoidosis
  • Ichthyosiform sarcoidosis
  • Hypopigmented sarcoidosis
  • Löfgren syndrome
  • Lupus pernio
  • Morpheaform sarcoidosis
  • Mucosal sarcoidosis
  • Neurosarcoidosis
  • Papular sarcoid
  • Scar sarcoid
  • Subcutaneous sarcoidosis
  • Systemic sarcoidosis
  • Ulcerative sarcoidosis
{{div col end}}

Treatment

Treatments for sarcoidosis vary greatly depending on the patient.[93] At least half of patients require no systemic therapy.[94] Most persons (>75%) only require symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin.[214] For persons presenting with lung symptoms, unless the respiratory impairment is devastating, active pulmonary sarcoidosis is observed usually without therapy for two to three months; if the inflammation does not subside spontaneously, therapy is instituted.[27]

Major categories of drug interventions include glucocorticoids, antimetabolites, biologic agents especially monoclonal anti-tumor necrosis factor antibodies.[94] Investigational treatments include specific antibiotic combinations and mesenchymal stem cells.[94] If drug intervention is indicated, a step-wise approach is often used to explore alternatives in order of increasing side effects and to monitor potentially toxic effects.[94]

Corticosteroids, most commonly prednisone or prednisolone, have been the standard treatment for many years.[50] In some people, this treatment can slow or reverse the course of the disease, but other people do not respond to steroid therapy. The use of corticosteroids in mild disease is controversial because in many cases the disease remits spontaneously.[95][96]

Antimetabolites

Antimetabolites, also categorized as steroid-sparing agents, such as azathioprine, methotrexate, mycophenolic acid, and leflunomide[97][98] are often used as alternatives to corticosteroids.[50][99] Of these, methotrexate is most widely used and studied.[99][100] Methotrexate is considered a first-line treatment in neurosarcoidosis, often in conjunction with corticosteroids.[43][99] Long-term treatment with methotrexate is associated with liver damage in about 10% of people and hence may be a significant concern in people with liver involvement and requires regular liver function test monitoring.[50] Methotrexate can also lead to pulmonary toxicity (lung damage), although this is fairly uncommon and more commonly it can confound the leukopenia caused by sarcoidosis.[50] Due to these safety concerns it is often recommended that methotrexate is combined with folic acid in order to prevent toxicity.[50] Azathioprine treatment can also lead to liver damage.[100] Leflunomide is being used as a replacement for methotrexate, possibly due to its purportedly lower rate of pulmonary toxicity.[100] Mycophenolic acid has been used successfully in uveal sarcoidosis,[101] neurosarcoidosis (especially CNS sarcoidosis; minimally effective in sarcoidosis myopathy),[102] and pulmonary sarcoidosis.[103][104]

Immunosuppressants

As the granulomas are caused by collections of immune system cells, particularly T cells, there has been some success using immunosuppressants (like cyclophosphamide, cladribine,[105] chlorambucil, and cyclosporine), immunomodulatory (pentoxifylline and thalidomide), and anti-tumor necrosis factor treatment[106][107] (such as infliximab, etanercept, golimumab, and adalimumab).[108][109][110]

In a clinical trial cyclosporine added to prednisone treatment failed to demonstrate any significant benefit over prednisone alone in people with pulmonary sarcoidosis, although there was evidence of increased toxicity from the addition of cyclosporine to the steroid treatment including infections, malignancies (cancers), hypertension, and kidney dysfunction.[100] Likewise chlorambucil and cyclophosphamide are seldom used in the treatment of sarcoidosis due to their high degree of toxicity, especially their potential for causing malignancies.[111] Infliximab has been used successfully to treat pulmonary sarcoidosis in clinical trials in a number of persons.[100] Etanercept, on the other hand, has failed to demonstrate any significant efficacy in people with uveal sarcoidosis in a couple of clinical trials.[100] Likewise golimumab has failed to show any benefit in persons with pulmonary sarcoidosis.[100] One clinical trial of adalimumab found treatment response in about half of subjects, which is similar to that seen with infliximab, but as adalimumab has better tolerability profile it may be preferred over infliximab.[100]

Specific organ treatments

Ursodeoxycholic acid has been used successfully as a treatment for cases with liver involvement.[112] Thalidomide has also been tried successfully as a treatment for treatment-resistant lupus pernio in a clinical trial, which may stem from its anti-TNF activity, although it failed to exhibit any efficacy in a pulmonary sarcoidosis clinical trial.[83][109] Cutaneous disease may be successfully managed with antimalarials (such as chloroquine and hydroxychloroquine) and the tetracycline antibiotic, minocycline.[27][109] Antimalarials have also demonstrated efficacy in treating sarcoidosis-induced hypercalcemia and neurosarcoidosis.[50] Long-term use of antimalarials is limited, however, by their potential to cause irreversible blindness and hence the need for regular ophthalmologic screening.[111] This toxicity is usually less of a problem with hydroxychloroquine than with chloroquine, although hydroxychloroquine can disturb the glucose homeostasis.[111]

Recently selective phosphodiesterase 4 (PDE4) inhibitors like apremilast (a thalidomide derivative), roflumilast, and the less subtype-selective PDE4 inhibitor, pentoxifylline, have been tried as a treatment for sarcoidosis, with successful results being obtained with apremilast in cutaneous sarcoidosis in a small open-label study.[113][114] Pentoxifylline has been used successfully to treat acute disease although its use is greatly limited by its gastrointestinal toxicity (mostly nausea, vomiting, and diarrhea).[98][100][111] Case reports have supported the efficacy of rituximab, an anti-CD20 monoclonal antibody and a clinical trial investigating atorvastatin as a treatment for sarcoidosis is under-way.[115][116] ACE inhibitors have been reported to cause remission in cutaneous sarcoidosis and improvement in pulmonary sarcoidosis, including improvement in pulmonary function, remodeling of lung parenchyma and prevention of pulmonary fibrosis in separate case series'.[117][118][119] Nicotine patches have been found to possess anti-inflammatory effects in sarcoidosis patients, although whether they had disease-modifying effects requires further investigation.[120] Antimycobacterial treatment (drugs that kill off mycobacteria, the causative agents behind tuberculosis and leprosy) has also proven itself effective in treating chronic cutaneous (that is, it affects the skin) sarcoidosis in one clinical trial.[121] Quercetin has also been tried as a treatment for pulmonary sarcoidosis with some early success in one small trial.[122]

Because of its uncommon nature, the treatment of male reproductive tract sarcoidosis is controversial. Since the differential diagnosis includes testicular cancer, some recommend orchiectomy, even if evidence of sarcoidosis in other organs is present. In the newer approach, testicular, epididymal biopsy and resection of the largest lesion has been proposed.[57]

Symptoms

People with sarcoidosis may have a range of symptoms that do not correspond with objective physical evidence of disease but that still decrease quality of life.[123]

Physical therapy, rehabilitation, and counseling can help avoid deconditioning,[123]{{rp|733}} and improve social participation, psychological well-being, and activity levels. Key aspects are avoiding exercise intolerance and muscle weakness.[123]{{rp|734}}

Low or moderate-intensity physical training has been shown to improve fatigue, psychological health, and physical functioning in people sarcoidosis without adverse effects.[124][125] Inspiratory muscle training has also decreased severe fatigue perception in subjects with early stages of sarcoidosis, as well as improving functional and maximal exercise capacity and respiratory muscle strength.[126] The duration, frequency, and physical intensity of exercise needs to accommodate impairments such as joint pain, muscle pain, and fatigue.[123]{{rp|734}}[125][127]

Neurostimulants such as methylphenidate and modafinil have shown some effectiveness as an adjunct for treatment of sarcoidosis fatigue.[123]{{rp|733}}[128]

Treatments for symptomatic neuropathic pain in sarcoidosis patients is similar to that for other causes, and include antidepressants, anticonvulsants and prolonged-release opioids, however only 30–60% of patients experience limited pain relief.[123]{{rp|733}}

Prognosis

The disease can remit spontaneously or become chronic, with exacerbations and remissions. In some persons, it can progress to pulmonary fibrosis and death. In benign cases, remission can occur in 24 to 36 months without treatment but regular follow ups are required. Some cases, however, may persist several decades.[50] Two-thirds of people with the condition achieve a remission within 10 years of the diagnosis.[129] When the heart is involved, the prognosis is generally less favourable, though corticosteroids appear effective in improving AV conduction.[130][131] The prognosis tends to be less favourable in African Americans than in white Americans.[68] In a Swedish population-based analysis, the majority of cases who did not have severe disease at diagnosis had comparable mortality to the general population.[132] The risk for premature death was markedly (2.3-fold) increased compared to the general population for a smaller group of cases with severe disease at diagnosis.[132]

Some 1990s studies indicated that persons with sarcoidosis appear to be at significantly increased risk for cancer, in particular lung cancer, lymphomas,[133] and cancer in other organs known to be affected in sarcoidosis.[134][135] In sarcoidosis-lymphoma syndrome, sarcoidosis is followed by the development of a lymphoproliferative disorder such as non-Hodgkin lymphoma.[136] This may be attributed to the underlying immunological abnormalities that occur during the sarcoidosis disease process.[137] Sarcoidosis can also follow cancer[138][139] or occur concurrently with cancer.[140][141] There have been reports of hairy cell leukemia,[142] acute myeloid leukemia,[143] and acute myeloblastic leukemia[144] associated with sarcoidosis.

Sometimes, sarcoidosis, even untreated, can be complicated by opportunistic infections.[145][146]

Epidemiology

Sarcoidosis most commonly affects young adults of both sexes, although studies have reported more cases in females. Incidence is highest for individuals younger than 40 and peaks in the age-group from 20 to 29 years; a second peak is observed for women over 50.[147][130]

Sarcoidosis occurs throughout the world in all races with an average incidence of 16.5 per 100,000 in men and 19 per 100,000 in women. The disease is most common in Northern European countries and the highest annual incidence of 60 per 100,000 is found in Sweden and Iceland. In the United Kingdom the prevalence is 16 in 100,000.[148] In the United States, sarcoidosis is more common in people of African descent than Caucasians, with annual incidence reported as 35.5 and 10.9 per 100,000, respectively.[149] Sarcoidosis is less commonly reported in South America, Spain, India, Canada, and the Philippines. There may be a higher susceptibility to sarcoidosis in those with celiac disease. An association between the two disorders has been suggested.[150]

There also has been a seasonal clustering observed in sarcoidosis-affected individuals.[151] In Greece about 70% of diagnoses occur between March and May every year, in Spain about 50% of diagnoses occur between April and June, and in Japan it is mostly diagnosed during June and July.[151]

The differing incidence across the world may be at least partially attributable to the lack of screening programs in certain regions of the world, and the overshadowing presence of other granulomatous diseases, such as tuberculosis, that may interfere with the diagnosis of sarcoidosis where they are prevalent.[130] There may also be differences in the severity of the disease between people of different ethnicities. Several studies suggest the presentation in people of African origin may be more severe and disseminated than for Caucasians, who are more likely to have asymptomatic disease.[59] Manifestation appears to be slightly different according to race and sex. Erythema nodosum is far more common in men than in women and in Caucasians than in other races. In Japanese persons, ophthalmologic and cardiac involvement are more common than in other races.[147]

It is more common in certain occupations, namely firefighters, educators, military personnel, persons who work in industries where pesticides are used, law enforcement, and healthcare personnel.[152] In the year after the September 11 attacks, the rate of sarcoidosis incidence went up four-fold (to 86 cases per 100,000).[45][152]

History

It was first described in 1877 by Dr. Jonathan Hutchinson, a dermatologist as a condition causing red, raised rashes on the face, arms, and hands.[15] In 1889 the term Lupus pernio was coined by Dr. Ernest Besnier, another dermatologist.[153] Later in 1892 lupus pernio's histology was defined.[153] In 1902 bone involvement was first described by a group of three doctors.[153] Between 1909 and 1910 uveitis in sarcoidosis was first described, and later in 1915 it was emphasised, by Dr. Schaumann, that it was a systemic condition.[153] This same year lung involvement was also described.[153] In 1937 uveoparotid fever was first described and likewise in 1941 Löfgren syndrome was first described.[153] In 1958 the first international conference on sarcoidosis was called in London, likewise the first USA sarcoidosis conference occurred in Washington, DC in the year 1961.[153] It has also been called Besnier-Boeck disease or Besnier-Boeck-Schaumann disease.[154]

Etymology

The word "sarcoidosis" comes from Greek [σάρκο-] sarcο- meaning "flesh", the suffix -(e)ido (from the Greek εἶδος -eidos [usually omitting the initial e in English as the diphthong epsilon-iota in Classic Greek stands for a long "i" = English ee]) meaning "type", " resembles" or "like", and -sis, a common suffix in Greek meaning "condition". Thus the whole word means "a condition that resembles crude flesh". The first cases of sarcoïdosis, which were recognised as a new pathological entity, in Scandinavia, at the end of the 19th century exhibited skin nodules resembling cutaneous sarcomas, hence the name initially given.

Society and culture

The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is an organisation of physicians involved in the diagnosis and treatment of sarcoidosis and related conditions.[155] WASOG publishes the journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases.[156] Additionally, the Foundation for Sarcoidosis Research (FSR) is devoted to supporting research into sarcoidosis and its possible treatments.[157]

There have been concerns that World Trade Center rescue workers are at a heightened risk for sarcoidosis.[158][159]

Comedian and actor Bernie Mac had sarcoidosis. In 2005, he mentioned that the disease was in remission.[160] His death on 9 August 2008 was caused by complications from pneumonia, which was precipitated by pulmonary scarring attributed to his sarcoidosis.{{citation needed|date=March 2017}}

In a 2014 letter to the British medical journal The Lancet, it was suggested that the French Revolution leader Maximilien Robespierre may have had sarcoidosis, causing him impairment during his time as head of the Reign of Terror.[161]

Pregnancy

Sarcoidosis generally does not prevent successful pregnancy and delivery; the increase in estrogen levels during pregnancy may even have a slightly beneficial immunomodulatory effect. In most cases, the course of the disease is unaffected by pregnancy, with improvement in a few cases and worsening of symptoms in very few cases, although it is worth noting that a number of the immunosuppressants (such as methotrexate, cyclophosphamide) used in corticosteroid-refractory sarcoidosis are known teratogens.[162]

References

1. ^{{cite book|last1=Konstantinidis|first1=G.|title=Elsevier's Dictionary of Medicine and Biology: in English, Greek, German, Italian and Latin|date=2005|publisher=Elsevier|isbn=9780080460123|page=1454|url=https://books.google.ca/books?id=lCKRIT-7X6UC&pg=PA1454|language=en}}
2. ^{{cite book|last1=Ferri|first1=Fred F.|title=Ferri's differential diagnosis : a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders|date=2010|publisher=Elsevier/Mosby|location=Philadelphia, PA|isbn=978-0323076999|page=Chapter S|edition=2nd}}
3. ^1 2 3 {{cite web|title=What Are the Signs and Symptoms of Sarcoidosis?|url=http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/signs|website=NHLBI|access-date=29 March 2016|date=June 14, 2013|deadurl=no|archive-url=https://web.archive.org/web/20160407101632/http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/signs|archive-date=7 April 2016|df=}}
4. ^1 2 3 4 5 6 7 8 9 10 11 12 13 {{cite web|title=What Is Sarcoidosis?|url=http://www.nhlbi.nih.gov/health/health-topics/topics/sarc|website=NHLBI|access-date=28 March 2016|date=June 14, 2013|deadurl=no|archive-url=https://web.archive.org/web/20160406004249/http://www.nhlbi.nih.gov/health/health-topics/topics/sarc|archive-date=6 April 2016|df=}}
5. ^1 2 {{cite journal | vauthors = Baughman RP, Culver DA, Judson MA | title = A concise review of pulmonary sarcoidosis | journal = American Journal of Respiratory and Critical Care Medicine | volume = 183 | issue = 5 | pages = 573–81 | date = March 2011 | pmid = 21037016 | pmc = 3081278 | doi = 10.1164/rccm.201006-0865CI }}
6. ^{{cite web|title=What Causes Sarcoidosis?|url=http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/causes|website=NHLBI|access-date=28 March 2016|date=June 14, 2013|deadurl=no|archive-url=https://web.archive.org/web/20160406004424/http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/causes|archive-date=6 April 2016|df=}}
7. ^1 2 3 {{cite journal | vauthors = Govender P, Berman JS | title = The Diagnosis of Sarcoidosis | journal = Clinics in Chest Medicine | volume = 36 | issue = 4 | pages = 585–602 | date = December 2015 | pmid = 26593135 | doi = 10.1016/j.ccm.2015.08.003 }}
8. ^1 {{cite journal | vauthors = Drent M, Cremers JP, Jansen TL | title = Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach | journal = Current Opinion in Rheumatology | volume = 26 | issue = 3 | pages = 276–84 | date = May 2014 | pmid = 24614277 | doi = 10.1097/bor.0000000000000052 }}
9. ^1 2 {{cite journal | vauthors = Judson MA | title = Corticosteroids in Sarcoidosis | journal = Rheumatic Diseases Clinics of North America | volume = 42 | issue = 1 | pages = 119–35, ix | date = February 2016 | pmid = 26611555 | doi = 10.1016/j.rdc.2015.08.012 }}
10. ^1 2 3 4 {{cite journal | vauthors = Wijsenbeek MS, Culver DA | title = Treatment of Sarcoidosis | journal = Clinics in Chest Medicine | volume = 36 | issue = 4 | pages = 751–67 | date = December 2015 | pmid = 26593147 | doi = 10.1016/j.ccm.2015.08.015 }}
11. ^1 {{cite journal | title = Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1545–1602 | date = October 2016 | pmid = 27733282 | pmc = 5055577 | doi = 10.1016/S0140-6736(16)31678-6 | author1 = GBD 2015 Disease Injury Incidence Prevalence Collaborators }}
12. ^1 {{cite journal | title = Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1459–1544 | date = October 2016 | pmid = 27733281 | pmc = 5388903 | doi = 10.1016/S0140-6736(16)31012-1 | author1 = GBD 2015 Mortality Causes of Death Collaborators }}
13. ^1 {{cite journal | vauthors = Kobak S | title = Sarcoidosis: a rheumatologist's perspective | journal = Therapeutic Advances in Musculoskeletal Disease | volume = 7 | issue = 5 | pages = 196–205 | date = October 2015 | pmid = 26425148 | pmc = 4572362 | doi = 10.1177/1759720x15591310 }}
14. ^1 2 3 4 {{cite web|title=Who Is at Risk for Sarcoidosis?|url=http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/atrisk|publisher=NHLBI|access-date=28 March 2016|date=June 14, 2013|deadurl=no|archive-url=https://web.archive.org/web/20160407101620/http://www.nhlbi.nih.gov/health/health-topics/topics/sarc/atrisk|archive-date=7 April 2016|df=}}
15. ^1 {{cite journal | vauthors = James DG, Sharma OP | title = From Hutchinson to now: a historical glimpse | journal = Current Opinion in Pulmonary Medicine | volume = 8 | issue = 5 | pages = 416–23 | date = September 2002 | pmid = 12172446 | doi = 10.1097/00063198-200209000-00013 | url = http://www.ildcare.eu/Downloads/artseninfo/History_of_sarcoidosis.pdf | archive-url = https://web.archive.org/web/20160304204934/http://www.ildcare.eu/Downloads/artseninfo/History_of_sarcoidosis.pdf | df = | deadurl = no | archive-date = 2016-03-04 }}
16. ^{{cite web |title=Lung Diseases: Sarcoidosis: Signs & Symptoms |access-date=May 9, 2009 |publisher=National Heart, Lung, and Blood Institute |url=http://www.nhlbi.nih.gov/health/dci/Diseases/sarc/sar_signsandsymptoms.html |deadurl=no |archive-url=https://web.archive.org/web/20090507163504/http://www.nhlbi.nih.gov/health/dci/Diseases/sarc/sar_signsandsymptoms.html |archive-date=May 7, 2009 |df= }}
17. ^{{cite web |title=Sarcoidosis Clinical Presentation |work=Medscape Reference |publisher=WebMD |access-date=19 February 2014 |date=6 February 2014 |url=http://emedicine.medscape.com/article/301914-clinical#showall |author1=Kamangar, N |author2=Rohani, P |author3=Shorr, AF |editor1=Peters, SP |editor2=Talavera, F |editor3=Rice, TD |editor4=Mosenifar, Z |deadurl=no |archive-url=https://web.archive.org/web/20140225084711/http://emedicine.medscape.com/article/301914-clinical#showall |archive-date=25 February 2014 |df= }}
18. ^1 2 3 {{cite web|title=Sarcoidosis: Interstitial Lung Diseases: Merck Manual Home Edition|url=http://www.merckmanuals.com/home/lung_and_airway_disorders/interstitial_lung_diseases/sarcoidosis.html|date=March 2008|access-date=19 February 2014|author=King, TE Jr.|work=The Merck Manual Home Edition|publisher=Merck Sharp & Dohme Corp|deadurl=no|archive-url=https://web.archive.org/web/20140220034716/http://www.merckmanuals.com/home/lung_and_airway_disorders/interstitial_lung_diseases/sarcoidosis.html|archive-date=20 February 2014|df=}}
19. ^{{cite journal | vauthors = Sweiss NJ, Patterson K, Sawaqed R, Jabbar U, Korsten P, Hogarth K, Wollman R, Garcia JG, Niewold TB, Baughman RP | title = Rheumatologic manifestations of sarcoidosis | journal = Seminars in Respiratory and Critical Care Medicine | volume = 31 | issue = 4 | pages = 463–73 | date = August 2010 | pmid = 20665396 | pmc = 3314339 | doi = 10.1055/s-0030-1262214 }}
20. ^1 {{cite journal | vauthors = Dempsey OJ, Paterson EW, Kerr KM, Denison AR | title = Sarcoidosis | journal = BMJ | volume = 339 | pages = b3206 | date = August 2009 | pmid = 19717499 | doi = 10.1136/bmj.b3206 }}
21. ^{{cite journal | vauthors = Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP | title = Sarcoidosis mimicking metastatic breast cancer | journal = Clinical Breast Cancer | volume = 7 | issue = 10 | pages = 804–10 | date = October 2007 | pmid = 18021484 | doi = 10.3816/CBC.2007.n.044 | url = http://linkinghub.elsevier.com/retrieve/pii/S1526-8209(11)70784-4 }}
22. ^{{cite journal | vauthors = Baughman RP, Lower EE, Gibson K | title = Pulmonary manifestations of sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e289–302 | date = June 2012 | pmid = 22579234 | doi = 10.1016/j.lpm.2012.03.019 }}
23. ^{{cite journal | vauthors = Fuhrer G, Myers JN | title = Intrathoracic sarcoidosis | journal = Disease-A-Month | volume = 55 | issue = 11 | pages = 661–74 | date = November 2009 | pmid = 19857641 | doi = 10.1016/j.disamonth.2009.04.009 }}
24. ^{{cite journal | vauthors = Nunes H, Uzunhan Y, Freynet O, Humbert M, Brillet PY, Kambouchner M, Valeyre D | title = Pulmonary hypertension complicating sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e303–16 | date = June 2012 | pmid = 22608948 | doi = 10.1016/j.lpm.2012.04.003 }}
25. ^Kumar and Clark, Clinical Medicine, 8th edition, p. 846.
26. ^1 {{cite journal | vauthors = Mañá J, Marcoval J | title = Skin manifestations of sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e355–74 | date = June 2012 | pmid = 22579238 | doi = 10.1016/j.lpm.2012.02.046 }}
27. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 {{cite book | title = Harrison's Principles of Internal Medicine | year = 2011 | url = | isbn = 978-0-07174889-6 | vauthors = Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J | edition = 18th | location = New York | publisher = McGraw-Hill Professional | work = }}
28. ^{{cite journal | vauthors = Heath CR, David J, Taylor SC | title = Sarcoidosis: Are there differences in your skin of color patients? | journal = Journal of the American Academy of Dermatology | volume = 66 | issue = 1 | pages = 121.e1–14 | date = January 2012 | pmid = 22000704 | doi = 10.1016/j.jaad.2010.06.068 }}
29. ^{{cite journal | vauthors = Lodha S, Sanchez M, Prystowsky S | title = Sarcoidosis of the skin: a review for the pulmonologist | journal = Chest | volume = 136 | issue = 2 | pages = 583–596 | date = August 2009 | pmid = 19666758 | doi = 10.1378/chest.08-1527 }}
30. ^1 {{cite book|last=James|first=WD; Berger, T; Dirk, M|title=Andrew's Diseases of the Skin: Clinical Dermatology|year=2006|publisher=Saunders Elsevier|location=Philadelphia|isbn=978-0808923510|edition=10th |pages=708–711}}
31. ^{{cite journal | vauthors = House NS, Welsh JP, English JC | title = Sarcoidosis-induced alopecia | journal = Dermatology Online Journal | volume = 18 | issue = 8 | pages = 4 | date = August 2012 | pmid = 22948054 | url = http://escholarship.org/uc/item/0fp92370 | archive-url = https://web.archive.org/web/20140302122043/http://escholarship.org/uc/item/0fp92370 | deadurl = no | archive-date = 2 March 2014 }}
32. ^{{cite journal | vauthors = Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K | title = HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis | journal = Heart Rhythm | volume = 11 | issue = 7 | pages = 1305–23 | date = July 2014 | pmid = 24819193 | doi = 10.1016/j.hrthm.2014.03.043 }}
33. ^{{cite journal | vauthors = Doughan AR, Williams BR | title = Cardiac sarcoidosis | journal = Heart | volume = 92 | issue = 2 | pages = 282–8 | date = February 2006 | pmid = 16415205 | pmc = 1860791 | doi = 10.1136/hrt.2005.080481 }}
34. ^1 {{cite journal | vauthors = Youssef G, Beanlands RS, Birnie DH, Nery PB | title = Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment | journal = Heart | volume = 97 | issue = 24 | pages = 2078–87 | date = December 2011 | pmid = 22116891 | doi = 10.1136/hrt.2011.226076 }}
35. ^{{cite journal | vauthors = Reuhl J, Schneider M, Sievert H, Lutz FU, Zieger G | title = Myocardial sarcoidosis as a rare cause of sudden cardiac death | journal = Forensic Science International | volume = 89 | issue = 3 | pages = 145–53 | date = October 1997 | pmid = 9363623 | doi = 10.1016/S0379-0738(97)00106-0 }}
36. ^{{cite journal | vauthors = Rajasenan V, Cooper ES | title = Myocardial sarcoidosis, bouts of ventricular tachycardia, psychiatric manifestations and sudden death. A case report | journal = Journal of the National Medical Association | volume = 61 | issue = 4 | pages = 306–9 | date = July 1969 | pmid = 5796402 | pmc = 2611747 | doi = }}
37. ^{{cite journal | vauthors = Chapelon-Abric C | title = Cardiac sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e317–30 | date = June 2012 | pmid = 22608949 | doi = 10.1016/j.lpm.2012.04.002 }}
38. ^{{cite journal | vauthors = Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R | title = Cardiac sarcoidosis-state of the art review | journal = Cardiovascular Diagnosis and Therapy | volume = 6 | issue = 1 | pages = 50–63 | date = February 2016 | pmid = 26885492 | pmc = 4731586 | doi = 10.3978/j.issn.2223-3652.2015.12.13 }}
39. ^{{cite journal | vauthors = Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P | title = Ocular sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e349–54 | date = June 2012 | pmid = 22595776 | doi = 10.1016/j.lpm.2012.04.004 }}
40. ^{{cite journal | vauthors = Jamilloux Y, Kodjikian L, Broussolle C, Sève P | title = Sarcoidosis and uveitis | journal = Autoimmunity Reviews | volume = 13 | issue = 8 | pages = 840–9 | date = August 2014 | pmid = 24704868 | doi = 10.1016/j.autrev.2014.04.001 }}
41. ^{{cite journal | vauthors = Papadia M, Herbort CP, Mochizuki M | title = Diagnosis of ocular sarcoidosis | journal = Ocular Immunology and Inflammation | volume = 18 | issue = 6 | pages = 432–41 | date = December 2010 | pmid = 21091056 | doi = 10.3109/09273948.2010.524344 }}
42. ^{{cite journal | vauthors = Qazi FA, Thorne JE, Jabs DA | title = Scleral nodule associated with sarcoidosis | journal = American Journal of Ophthalmology | volume = 136 | issue = 4 | pages = 752–4 | date = October 2003 | pmid = 14516826 | doi = 10.1016/S0002-9394(03)00454-9 }}
43. ^1 2 3 4 5 6 7 {{cite journal | vauthors = Nozaki K, Judson MA | title = Neurosarcoidosis: Clinical manifestations, diagnosis and treatment | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e331–48 | date = June 2012 | pmid = 22595777 | doi = 10.1016/j.lpm.2011.12.017 }}
44. ^{{cite journal | vauthors = Said G, Lacroix C, Planté-Bordeneuve V, Le Page L, Pico F, Presles O, Senant J, Remy P, Rondepierre P, Mallecourt J | title = Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients | journal = Brain | volume = 125 | issue = Pt 2 | pages = 264–75 | date = February 2002 | pmid = 11844727 | doi = 10.1093/brain/awf027 }}
45. ^1 2 3 4 {{cite journal | vauthors = Chen ES, Moller DR | title = Sarcoidosis--scientific progress and clinical challenges | journal = Nature Reviews. Rheumatology | volume = 7 | issue = 8 | pages = 457–67 | date = July 2011 | pmid = 21750528 | doi = 10.1038/nrrheum.2011.93 }}
46. ^{{cite journal | vauthors = Tavee J, Culver D | title = Sarcoidosis and small-fiber neuropathy | journal = Current Pain and Headache Reports | volume = 15 | issue = 3 | pages = 201–6 | date = June 2011 | pmid = 21298560 | doi = 10.1007/s11916-011-0180-8 }}
47. ^{{cite journal | vauthors = Heij L, Dahan A, Hoitsma E | title = Sarcoidosis and pain caused by small-fiber neuropathy | journal = Pain Research and Treatment | volume = 2012 | pages = 1–6 | year = 2012 | pmid = 23304492 | pmc = 3523152 | doi = 10.1155/2012/256024 }}
48. ^1 2 3 4 5 6 7 {{cite journal | vauthors = Vardhanabhuti V, Venkatanarasimha N, Bhatnagar G, Maviki M, Iyengar S, Adams WM, Suresh P | title = Extra-pulmonary manifestations of sarcoidosis | journal = Clinical Radiology | volume = 67 | issue = 3 | pages = 263–76 | date = March 2012 | pmid = 22094184 | doi = 10.1016/j.crad.2011.04.018 }}
49. ^{{cite journal | vauthors = Porter N, Beynon HL, Randeva HS | title = Endocrine and reproductive manifestations of sarcoidosis | journal = QJM | volume = 96 | issue = 8 | pages = 553–61 | date = August 2003 | pmid = 12897340 | doi = 10.1093/qjmed/hcg103 | url = http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12897340 }}
50. ^{{cite journal | vauthors = Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL | title = Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D | journal = The New England Journal of Medicine | volume = 305 | issue = 8 | pages = 440–3 | date = August 1981 | pmid = 6894783 | doi = 10.1056/NEJM198108203050807 }}
51. ^{{Cite book |title = Rheumatology Diagnosis & Therapies |edition=2nd | publisher = Lippincott Williams & Wilkins | location = Philadelphia | year = 2005 | page = 342 }}
52. ^1 {{cite journal | vauthors = Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E | title = Prevalence of hypothyroidism and Graves disease in sarcoidosis | journal = Chest | volume = 130 | issue = 2 | pages = 526–32 | date = August 2006 | pmid = 16899854 | doi = 10.1378/chest.130.2.526 }}
53. ^{{cite journal | vauthors = Manchanda A, Patel S, Jiang JJ, Babu AR | title = Thyroid: an unusual hideout for sarcoidosis | journal = Endocrine Practice | volume = 19 | issue = 2 | pages = e40–3 | date = March–April 2013 | pmid = 23337134 | doi = 10.4158/EP12131.CR | url = http://aace.metapress.com/content/h35854138g847h80/fulltext.pdf }}
54. ^{{cite journal | vauthors = Tokala H, Polsani K, Kalavakunta JK | title = Gastric sarcoidosis: a rare clinical presentation | journal = Case Reports in Gastrointestinal Medicine | volume = 2013 | pages = 260704 | date = 2013-01-01 | pmid = 24368949 | pmc = 3867894 | doi = 10.1155/2013/260704 }}
55. ^1 2 3 4 5 6 {{cite journal | vauthors = Holmes J, Lazarus A | title = Sarcoidosis: extrathoracic manifestations | journal = Disease-A-Month | volume = 55 | issue = 11 | pages = 675–92 | date = November 2009 | pmid = 19857642 | doi = 10.1016/j.disamonth.2009.05.002 }}
56. ^{{cite journal | vauthors = Vera C, Funaro D, Bouffard D | title = Vulvar sarcoidosis: case report and review of the literature | journal = Journal of Cutaneous Medicine and Surgery | volume = 17 | issue = 4 | pages = 287–90 | date = July–August 2013 | pmid = 23815963 | doi = 10.2310/7750.2012.12083 }}
57. ^1 2 3 {{cite journal | vauthors = Paknejad O, Gilani MA, Khoshchehreh M | title = Testicular masses in a man with a plausible sarcoidosis | journal = Indian Journal of Urology | volume = 27 | issue = 2 | pages = 269–71 | date = April 2011 | pmid = 21814320 | pmc = 3142840 | doi = 10.4103/0970-1591.82848 }}
58. ^{{cite journal | vauthors = Cremers JP, Drent M, Baughman RP, Wijnen PA, Koek GH | title = Therapeutic approach of hepatic sarcoidosis | journal = Current Opinion in Pulmonary Medicine | volume = 18 | issue = 5 | pages = 472–82 | date = September 2012 | pmid = 22617809 | doi = 10.1097/MCP.0b013e3283541626 }}
59. ^1 {{cite journal | vauthors = | title = Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 | journal = American Journal of Respiratory and Critical Care Medicine | volume = 160 | issue = 2 | pages = 736–55 | date = August 1999 | pmid = 10430755 | doi = 10.1164/ajrccm.160.2.ats4-99 }}
60. ^{{cite journal | vauthors = Wurm K, Löhr G | title = Immuno-cytological blood tests in cases of sarcoidosis | journal = Sarcoidosis | volume = 3 | issue = 1 | pages = 52–9 | date = March 1986 | pmid = 3033787 | doi = }}
61. ^1 2 3 {{cite book |vauthors=Fausto N, Abbas A | title = Robbins and Cotran Pathologic Basis of disease. | date = 2004 | publisher = Elsevier/Saunders | edition = 7th | location = Philadelphia, PA | isbn = 978-0721601878 | pages = 737–9 }}
62. ^{{cite journal | vauthors = Chen HC, Kang BH, Lai CT, Lin YS | title = Sarcoidal granuloma in cervical lymph nodes | journal = Journal of the Chinese Medical Association | volume = 68 | issue = 7 | pages = 339–42 | date = July 2005 | pmid = 16038376 | doi = 10.1016/S1726-4901(09)70172-8 }}
63. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 {{cite journal | vauthors = Rao DA, Dellaripa PF | title = Extrapulmonary manifestations of sarcoidosis | journal = Rheumatic Diseases Clinics of North America | volume = 39 | issue = 2 | pages = 277–97 | date = May 2013 | pmid = 23597964 | pmc = 3756667 | doi = 10.1016/j.rdc.2013.02.007 }}
64. ^{{cite journal | vauthors = Shimamura Y, Taniguchi Y, Yoshimatsu R, Kawase S, Yamagami T, Terada Y | title = Granulomatous periostitis and tracheal involvement in sarcoidosis | journal = Rheumatology | volume = 55 | issue = 1 | pages = 102 | date = January 2016 | pmid = 26320137 | doi = 10.1093/rheumatology/kev319 }}
65. ^{{cite journal | vauthors = Korkmaz C, Efe B, Tel N, Kabukçuoglu S, Erenoglu E | title = Sarcoidosis with palpable nodular myositis, periostitis and large-vessel vasculitis stimulating Takayasu's arteritis | journal = Rheumatology | volume = 38 | issue = 3 | pages = 287–8 | date = March 1999 | pmid = 10325674 | doi = 10.1093/rheumatology/38.3.287 }}
66. ^{{cite journal | vauthors = Rossman MD, Kreider ME | title = Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis) | journal = Proceedings of the American Thoracic Society | volume = 4 | issue = 5 | pages = 453–6 | date = August 2007 | pmid = 17684288 | doi = 10.1513/pats.200607-138MS }}
67. ^{{cite journal | vauthors = Cathcart S, Sami N, Elewski B | title = Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors | journal = Journal of Drugs in Dermatology | volume = 11 | issue = 5 | pages = 609–12 | date = May 2012 | pmid = 22527429 }}
68. ^1 2 3 4 5 6 {{cite web |title=Sarcoidosis |work=Medscape Reference |publisher=WebMD |access-date=19 February 2014 |date=6 February 2014 |url=http://emedicine.medscape.com/article/301914-overview#showall |author1=Kamangar, N |author2=Rohani, P |author3=Shorr, AF |editor1=Peters, SP |editor2=Talavera, F |editor3=Rice, TD |editor4=Mosenifar, Z |deadurl=no |archive-url=https://web.archive.org/web/20140210163445/http://emedicine.medscape.com/article/301914-overview#showall |archive-date=10 February 2014 |df= }}
69. ^1 {{Cite journal|last=Rossides|first=Marios|last2=Grunewald|first2=Johan|last3=Eklund|first3=Anders|last4=Kullberg|first4=Susanna|last5=Giuseppe|first5=Daniela Di|last6=Askling|first6=Johan|last7=Arkema|first7=Elizabeth V.|date=2018-01-01|title=Familial Aggregation and Heritability of Sarcoidosis: A Swedish Nested Case-Control Study|url=http://erj.ersjournals.com/content/early/2018/06/14/13993003.00385-2018|journal=European Respiratory Journal|volume=52|issue=2|language=en|pages=1800385|doi=10.1183/13993003.00385-2018|issn=0903-1936|pmid=29946010}}
70. ^{{cite journal | vauthors = Iannuzzi MC | title = Advances in the genetics of sarcoidosis | journal = Proceedings of the American Thoracic Society | volume = 4 | issue = 5 | pages = 457–60 | date = August 2007 | pmid = 17684289 | doi = 10.1513/pats.200606-136MS }}
71. ^{{cite journal | vauthors = Spagnolo P, Grunewald J | title = Recent advances in the genetics of sarcoidosis | journal = Journal of Medical Genetics | volume = 50 | issue = 5 | pages = 290–7 | date = May 2013 | pmid = 23526832 | doi = 10.1136/jmedgenet-2013-101532 }}
72. ^{{cite journal | vauthors = Grunewald J, Eklund A, Olerup O | title = Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients | journal = American Journal of Respiratory and Critical Care Medicine | volume = 169 | issue = 6 | pages = 696–702 | date = March 2004 | pmid = 14656748 | doi = 10.1164/rccm.200303-459OC | citeseerx = 10.1.1.321.2788 }}
73. ^{{cite journal | vauthors = Grunewald J | title = Review: role of genetics in susceptibility and outcome of sarcoidosis | journal = Seminars in Respiratory and Critical Care Medicine | volume = 31 | issue = 4 | pages = 380–9 | date = August 2010 | pmid = 20665388 | doi = 10.1055/s-0030-1262206 }}
74. ^{{cite journal | vauthors = Gialafos E, Triposkiadis F, Kouranos V, Rapti A, Kosmas I, Manali E, Giamouzis G, Elezoglou A, Peros I, Anagnostopoulou O, Koulouris N, Gazouli M | title = Relationship between tumor necrosis factor-α (TNFA) gene polymorphisms and cardiac sarcoidosis | journal = In Vivo | volume = 28 | issue = 6 | pages = 1125–9 | date = 2014-12-01 | pmid = 25398810 }}
75. ^{{cite journal | vauthors = Saidha S, Sotirchos ES, Eckstein C | title = Etiology of sarcoidosis: does infection play a role? | journal = The Yale Journal of Biology and Medicine | volume = 85 | issue = 1 | pages = 133–41 | date = March 2012 | pmid = 22461752 | pmc = 3313528 }}
76. ^{{cite journal | vauthors = Gupta D, Agarwal R, Aggarwal AN, Jindal SK | title = Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis | journal = The European Respiratory Journal | volume = 30 | issue = 3 | pages = 508–16 | date = September 2007 | pmid = 17537780 | doi = 10.1183/09031936.00002607 }}
77. ^{{cite journal | vauthors = Almenoff PL, Johnson A, Lesser M, Mattman LH | title = Growth of acid fast L forms from the blood of patients with sarcoidosis | journal = Thorax | volume = 51 | issue = 5 | pages = 530–3 | date = May 1996 | pmid = 8711683 | pmc = 473601 | doi = 10.1136/thx.51.5.530 | url = http://thorax.bmj.com/cgi/pmidlookup?view=long&pmid=8711683 }}
78. ^{{cite journal | vauthors = Morgenthau AS, Iannuzzi MC | title = Recent advances in sarcoidosis | journal = Chest | volume = 139 | issue = 1 | pages = 174–82 | date = January 2011 | pmid = 21208877 | doi = 10.1378/chest.10-0188 | url = http://journal.publications.chestnet.org/data/Journals/CHEST/20389/100188.pdf }}
79. ^{{cite journal | vauthors = Padilla ML, Schilero GJ, Teirstein AS | title = Donor-acquired sarcoidosis | journal = Sarcoidosis, Vasculitis, and Diffuse Lung Diseases | volume = 19 | issue = 1 | pages = 18–24 | date = March 2002 | pmid = 12002380 }}
80. ^{{cite journal | vauthors = Romagnani S | title = The Th1/Th2 paradigm | journal = Immunology Today | volume = 18 | issue = 6 | pages = 263–6 | date = June 1997 | pmid = 9190109 | doi = 10.1016/S0167-5699(97)80019-9 }}
81. ^{{cite journal | vauthors = Morell F, Levy G, Orriols R, Ferrer J, De Gracia J, Sampol G | title = Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis | journal = Chest | volume = 121 | issue = 4 | pages = 1239–44 | date = April 2002 | pmid = 11948059 | doi = 10.1378/chest.121.4.1239 | url = http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=11948059 }}
82. ^1 2 {{cite journal | vauthors = Müller-Quernheim J, Prasse A, Zissel G | title = Pathogenesis of sarcoidosis | journal = Presse Médicale | volume = 41 | issue = 6 Pt 2 | pages = e275–87 | date = June 2012 | pmid = 22595775 | doi = 10.1016/j.lpm.2012.03.018 }}
83. ^1 2 {{cite journal | vauthors = Bargagli E, Olivieri C, Rottoli P | title = Cytokine modulators in the treatment of sarcoidosis | journal = Rheumatology International | volume = 31 | issue = 12 | pages = 1539–44 | date = December 2011 | pmid = 21644041 | doi = 10.1007/s00296-011-1969-9 }}
84. ^{{cite journal | vauthors = Kettritz R, Goebel U, Fiebeler A, Schneider W, Luft F | title = The protean face of sarcoidosis revisited | journal = Nephrology, Dialysis, Transplantation | volume = 21 | issue = 10 | pages = 2690–4 | date = October 2006 | pmid = 16861724 | doi = 10.1093/ndt/gfl369 | url = http://ndt.oxfordjournals.org/content/21/10/2690.full.pdf }}
85. ^{{cite journal | vauthors = Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R | title = Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients | journal = Clinical Rheumatology | volume = 26 | issue = 11 | pages = 1969–71 | date = November 2007 | pmid = 17340045 | doi = 10.1007/s10067-007-0594-1 }}
86. ^{{cite journal | vauthors = Parrish S, Turner JF | title = Diagnosis of sarcoidosis | journal = Disease-A-Month | volume = 55 | issue = 11 | pages = 693–703 | date = November 2009 | pmid = 19857643 | doi = 10.1016/j.disamonth.2009.06.001 }}
87. ^{{cite journal | vauthors = Hawtin KE, Roddie ME, Mauri FA, Copley SJ | title = Pulmonary sarcoidosis: the 'Great Pretender' | journal = Clinical Radiology | volume = 65 | issue = 8 | pages = 642–50 | date = August 2010 | pmid = 20599067 | doi = 10.1016/j.crad.2010.03.004 }}
88. ^{{cite journal | vauthors = Miliauskas S, Zemaitis M, Sakalauskas R | title = Sarcoidosis--moving to the new standard of diagnosis? | journal = Medicina | volume = 46 | issue = 7 | pages = 443–6 | year = 2010 | pmid = 20966615 | url = http://medicina.kmu.lt/1007/1007-01e.pdf | archive-url = https://web.archive.org/web/20140226213947/http://medicina.kmu.lt/1007/1007-01e.pdf | df = | deadurl = no | archive-date = 2014-02-26 | doi = 10.3390/medicina46070063 }}
89. ^1 2 {{cite web |title=Sarcoidosis Workup |work=Medscape Reference |publisher=WebMD |access-date=19 February 2014 |date=6 February 2014 |url=http://emedicine.medscape.com/article/301914-workup#showall |author1=Kamangar, N |author2=Rohani, P |author3=Shorr, AF |editor1=Peters, SP |editor2=Talavera, F |editor3=Rice, TD |editor4=Mosenifar, Z |deadurl=no |archive-url=https://web.archive.org/web/20140301113850/http://emedicine.medscape.com/article/301914-workup#showall |archive-date=1 March 2014 |df= }}
90. ^{{cite journal |vauthors=Allmendinger A, Perone R |title=Case of the Month |journal=Diagnostic Imaging |volume=31 |issue=9 |pages=10 |year=2009|url=http://www.diagnosticimaging.com/display/article/113619/1451377}}
91. ^{{cite journal |author=Joanne Mambretti |year=2004 |title=Chest X-ray Stages of Sarcoidosis |journal=Journal of Insurance Medicine |pages=91–92 |url=http://www.aaimedicine.org/journal-of-insurance-medicine/jim/2004/036-01-0091.pdf |access-date=June 3, 2012 |deadurl=no |archive-url=https://web.archive.org/web/20140709192802/http://aaimedicine.org/journal-of-insurance-medicine/jim/2004/036-01-0091.pdf |archive-date=July 9, 2014 |df= }}
92. ^{{cite journal | vauthors = Andonopoulos AP, Papadimitriou C, Melachrinou M, Meimaris N, Vlahanastasi C, Bounas A, Georgiou P | title = Asymptomatic gastrocnemius muscle biopsy: an extremely sensitive and specific test in the pathologic confirmation of sarcoidosis presenting with hilar adenopathy | journal = Clinical and Experimental Rheumatology | volume = 19 | issue = 5 | pages = 569–72 | year = 2001 | pmid = 11579718 | url = http://www.clinexprheumatol.org/article.asp?a=1137 | format = PDF | archive-url = https://web.archive.org/web/20160224082455/http://www.clinexprheumatol.org/article.asp?a=1137 | df = | deadurl = no | archive-date = 2016-02-24 }}
93. ^{{cite journal | vauthors = Baughman RP, Lower EE | title = Treatment of Sarcoidosis | journal = Clinical Reviews in Allergy & Immunology | volume = 49 | issue = 1 | pages = 79–92 | date = August 2015 | pmid = 25989728 | doi = 10.1007/s12016-015-8492-9 }}
94. ^1 2 3 {{cite journal | vauthors = Baughman RP, Grutters JC | title = New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches | journal = The Lancet. Respiratory Medicine | volume = 3 | issue = 10 | pages = 813–22 | date = October 2015 | pmid = 26204816 | doi = 10.1016/S2213-2600(15)00199-X }}
95. ^{{cite journal | vauthors = White ES, Lynch JP | title = Current and emerging strategies for the management of sarcoidosis | journal = Expert Opinion on Pharmacotherapy | volume = 8 | issue = 9 | pages = 1293–311 | date = June 2007 | pmid = 17563264 | doi = 10.1517/14656566.8.9.1293 }}
96. ^{{cite journal | vauthors = Paramothayan NS, Lasserson TJ, Jones PW | title = Corticosteroids for pulmonary sarcoidosis | journal = The Cochrane Database of Systematic Reviews | issue = 2 | pages = CD001114 | date = April 2005 | pmid = 15846612 | doi = 10.1002/14651858.CD001114.pub2 | df = }}
97. ^{{cite journal | vauthors = Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, Chapman JT, Culver DA | title = Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis | journal = The European Respiratory Journal | volume = 38 | issue = 5 | pages = 1145–50 | date = November 2011 | pmid = 21565914 | doi = 10.1183/09031936.00195010 | df = }}
98. ^1 {{cite journal | vauthors = Panselinas E, Judson MA | title = Acute pulmonary exacerbations of sarcoidosis | journal = Chest | volume = 142 | issue = 4 | pages = 827–836 | date = October 2012 | pmid = 23032450 | doi = 10.1378/chest.12-1060 | url = http://journal.publications.chestnet.org/data/Journals/CHEST/25163/chest_142_4_827.pdf }}
99. ^1 2 {{cite journal | vauthors = King CS, Kelly W | title = Treatment of sarcoidosis | journal = Disease-A-Month | volume = 55 | issue = 11 | pages = 704–18 | date = November 2009 | pmid = 19857644 | doi = 10.1016/j.disamonth.2009.06.002 }}
100. ^1 2 3 4 5 6 7 8 {{cite journal | vauthors = Baughman RP, Nunes H, Sweiss NJ, Lower EE | title = Established and experimental medical therapy of pulmonary sarcoidosis | journal = The European Respiratory Journal | volume = 41 | issue = 6 | pages = 1424–38 | date = June 2013 | pmid = 23397302 | doi = 10.1183/09031936.00060612 }}
101. ^{{cite journal | vauthors = Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS | title = Mycophenolate mofetil therapy for sarcoidosis-associated uveitis | journal = Ocular Immunology and Inflammation | volume = 17 | issue = 3 | pages = 185–90 | date = May–June 2009 | pmid = 19585361 | doi = 10.1080/09273940902862992 }}
102. ^{{cite journal | vauthors = Androdias G, Maillet D, Marignier R, Pinède L, Confavreux C, Broussolle C, Vukusic S, Sève P | title = Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy | journal = Neurology | volume = 76 | issue = 13 | pages = 1168–72 | date = March 2011 | pmid = 21444902 | doi = 10.1212/WNL.0b013e318212aafb }}
103. ^{{cite journal | vauthors = Judson MA | title = The treatment of pulmonary sarcoidosis | journal = Respiratory Medicine | volume = 106 | issue = 10 | pages = 1351–61 | date = October 2012 | pmid = 22495110 | doi = 10.1016/j.rmed.2012.01.013 }}
104. ^{{cite journal | vauthors = Brill AK, Ott SR, Geiser T | title = Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study | journal = Respiration; International Review of Thoracic Diseases | volume = 86 | issue = 5 | pages = 376–83 | year = 2013 | pmid = 23295253 | doi = 10.1159/000345596 }}
105. ^{{cite journal | vauthors = Tikoo RK, Kupersmith MJ, Finlay JL | title = Treatment of refractory neurosarcoidosis with cladribine | journal = The New England Journal of Medicine | volume = 350 | issue = 17 | pages = 1798–9 | date = April 2004 | pmid = 15103013 | doi = 10.1056/NEJMc032345 }}
106. ^{{cite journal | vauthors = Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L | title = Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review | journal = Seminars in Arthritis and Rheumatism | volume = 42 | issue = 1 | pages = 89–103 | date = August 2012 | pmid = 22387045 | doi = 10.1016/j.semarthrit.2011.12.006 }}
107. ^{{cite journal | vauthors = Antoniu SA | title = Targeting the TNF-alpha pathway in sarcoidosis | journal = Expert Opinion on Therapeutic Targets | volume = 14 | issue = 1 | pages = 21–9 | date = January 2010 | pmid = 20001207 | doi = 10.1517/14728220903449244 }}
108. ^1 {{cite web |title=Sarcoidosis Treatment & Management |work=Medscape Reference |publisher=WebMD |access-date=19 February 2014 |date=6 February 2014 |url=http://emedicine.medscape.com/article/301914-clinical#showall |author1=Kamangar, N |author2=Rohani, P |author3=Shorr, AF |editor1=Peters, SP |editor2=Talavera, F |editor3=Rice, TD |editor4=Mosenifar, Z |deadurl=no |archive-url=https://web.archive.org/web/20140225084711/http://emedicine.medscape.com/article/301914-clinical#showall |archive-date=25 February 2014 |df= }}
109. ^1 2 {{cite journal | vauthors = Beegle SH, Barba K, Gobunsuy R, Judson MA | title = Current and emerging pharmacological treatments for sarcoidosis: a review | journal = Drug Design, Development and Therapy | volume = 7 | pages = 325–38 | year = 2013 | pmid = 23596348 | pmc = 3627473 | doi = 10.2147/DDDT.S31064 }}
110. ^{{cite journal | vauthors = Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N | title = Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis | journal = Therapeutics and Clinical Risk Management | volume = 4 | issue = 6 | pages = 1305–13 | date = December 2008 | pmid = 19337437 | pmc = 2643111 | doi = 10.2147/TCRM.S967 }}
111. ^1 2 3 {{cite journal | vauthors = Dastoori M, Fedele S, Leao JC, Porter SR | title = Sarcoidosis - a clinically orientated review | journal = Journal of Oral Pathology & Medicine | volume = 42 | issue = 4 | pages = 281–9 | date = April 2013 | pmid = 22845844 | doi = 10.1111/j.1600-0714.2012.01198.x }}
112. ^{{cite journal | vauthors = Bakker GJ, Haan YC, Maillette de Buy Wenniger LJ, Beuers U | title = Sarcoidosis of the liver: to treat or not to treat? | journal = The Netherlands Journal of Medicine | volume = 70 | issue = 8 | pages = 349–56 | date = October 2012 | pmid = 23065982 | url = http://www.njmonline.nl/getpdf.php?id=10000876 | author3 = Maillette de Buy Wenniger LJ | format = PDF | archive-url = https://web.archive.org/web/20140518102045/http://www.njmonline.nl/getpdf.php?id=10000876 | df = | deadurl = no | archive-date = 2014-05-18 }}
113. ^{{cite journal | vauthors = Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE | title = Efficacy and safety of apremilast in chronic cutaneous sarcoidosis | journal = Archives of Dermatology | volume = 148 | issue = 2 | pages = 262–4 | date = February 2012 | pmid = 22004880 | doi = 10.1001/archdermatol.2011.301 | url = http://archderm.jamanetwork.com/data/Journals/DERM/22504/dlt110003_262a_264.pdf | archive-url = https://web.archive.org/web/20140226043859/http://archderm.jamanetwork.com/data/Journals/DERM/22504/dlt110003_262a_264.pdf | df = | deadurl = no | archive-date = 2014-02-26 }}
114. ^{{ClinicalTrialsGov|NCT01830959|Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)}}
115. ^{{cite journal | vauthors = Belkhou A, Younsi R, El Bouchti I, El Hassani S | title = Rituximab as a treatment alternative in sarcoidosis | journal = Joint, Bone, Spine | volume = 75 | issue = 4 | pages = 511–2 | date = July 2008 | pmid = 18562234 | doi = 10.1016/j.jbspin.2008.01.025 }}
116. ^{{ClinicalTrialsGov|NCT00279708|Atorvastatin to Treat Pulmonary Sarcoidosis}}
117. ^{{cite journal | vauthors = Kaura V, Kaura NV, Kaura BN, Kaura CS | title = Angiotensin-converting enzyme inhibitors in the treatment of sarcoidosis and association with ACE gene polymorphism: case series | journal = The Indian Journal of Chest Diseases & Allied Sciences | volume = 55 | issue = 2 | pages = 105–7 | year = 2013 | pmid = 24047001 }}
118. ^{{cite journal | vauthors = Kaura V, Kaura SH, Kaura CS | title = ACE Inhibitor in the treatment of cutaneous and lymphatic sarcoidosis | journal = American Journal of Clinical Dermatology | volume = 8 | issue = 3 | pages = 183–6 | date = 2007 | pmid = 17492847 | doi = 10.2165/00128071-200708030-00006 }}
119. ^{{cite journal | vauthors = Rosenbloom J, Castro SV, Jimenez SA | title = Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies | journal = Annals of Internal Medicine | volume = 152 | issue = 3 | pages = 159–66 | date = February 2010 | pmid = 20124232 | doi = 10.7326/0003-4819-152-3-201002020-00007 }}
120. ^{{cite journal | vauthors = Julian MW, Shao G, Schlesinger LS, Huang Q, Cosmar DG, Bhatt NY, Culver DA, Baughman RP, Wood KL, Crouser ED | title = Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis | journal = Chest | volume = 143 | issue = 2 | pages = 461–470 | date = February 2013 | pmid = 22878868 | doi = 10.1378/chest.12-0383 | url = http://journal.publications.chestnet.org/pdfaccess.ashx?ResourceID=5237502&PDFSource=13 | format = PDF }}
121. ^{{cite journal | vauthors = Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE | title = Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study | journal = JAMA Dermatology | volume = 149 | issue = 9 | pages = 1040–9 | date = September 2013 | pmid = 23863960 | pmc = 3927541 | doi = 10.1001/jamadermatol.2013.4646 }}
122. ^{{cite journal | vauthors = Boots AW, Drent M, de Boer VC, Bast A, Haenen GR | title = Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis | journal = Clinical Nutrition | volume = 30 | issue = 4 | pages = 506–12 | date = August 2011 | pmid = 21324570 | doi = 10.1016/j.clnu.2011.01.010 }}
123. ^1 2 3 4 5 {{cite journal | vauthors = Drent M, Strookappe B, Hoitsma E, De Vries J | title = Consequences of Sarcoidosis | journal = Clinics in Chest Medicine | volume = 36 | issue = 4 | pages = 727–37 | date = December 2015 | pmid = 26593145 | doi = 10.1016/j.ccm.2015.08.013 }}
124. ^{{cite journal | vauthors = Marcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, Lenssen A | title = Does physical training reduce fatigue in sarcoidosis? | journal = Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG | volume = 32 | issue = 1 | pages = 53–62 | date = June 2015 | pmid = 26237356 | doi = | url = }}
125. ^1 {{cite journal | vauthors = Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M | title = Benefits of Physical Training in Sarcoidosis | journal = Lung | volume = 193 | issue = 5 | pages = 701–8 | date = October 2015 | pmid = 26286208 | doi = 10.1007/s00408-015-9784-9 }}
126. ^{{cite journal | vauthors = Karadallı MN, Boşnak-Güçlü M, Camcıoğlu B, Kokturk N, Türktaş H | title = Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial | journal = Respiratory Care | volume = 61 | issue = 4 | pages = 483–94 | date = April 2016 | pmid = 26715771 | doi = 10.4187/respcare.04312 }}
127. ^{{cite book | vauthors = Spruit MA, Wouters EF, Gosselink R |title= Rehabilitation programmes in sarcoidosis: a multidisciplinary approach |journal= European Respiratory Monograph |date= 2005 |volume=32 |issue=3 |pages= 316–326 | doi = 10.1183/1025448x.00032021 |isbn= 9781904097372 }}
128. ^{{cite journal | vauthors = Baughman RP, Nunes H | title = Sarcoidosis-associated fatigue: an often forgotten symptom--author reply | journal = Expert Review of Clinical Immunology | volume = 9 | issue = 2 | pages = 111 | date = February 2013 | pmid = 23390941 | doi = 10.1586/ECI.12.93 }}
129. ^{{cite web|title=What Is Sarcoidosis?|work=National Heart, Lung and Blood Institute|publisher=National Institutes of Health|date=14 June 2013|access-date=21 February 2014|url=https://www.nhlbi.nih.gov/health/health-topics/topics/sarc/|deadurl=no|archive-url=https://web.archive.org/web/20140227004511/https://www.nhlbi.nih.gov/health/health-topics/topics/sarc/|archive-date=27 February 2014|df=}}
130. ^1 2 {{cite journal | vauthors = Syed J, Myers R | title = Sarcoid heart disease | journal = The Canadian Journal of Cardiology | volume = 20 | issue = 1 | pages = 89–93 | date = January 2004 | pmid = 14968147 }}
131. ^{{cite journal | vauthors = Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB | title = Corticosteroid therapy for cardiac sarcoidosis: a systematic review | journal = The Canadian Journal of Cardiology | volume = 29 | issue = 9 | pages = 1034–41 | date = September 2013 | pmid = 23623644 | doi = 10.1016/j.cjca.2013.02.004 }}
132. ^1 {{cite journal | vauthors = Rossides M, Kullberg S, Askling J, Eklund A, Grunewald J, Arkema EV | title = Sarcoidosis mortality in Sweden: a population-based cohort study | journal = The European Respiratory Journal | volume = 51 | issue = 2 | pages = 1701815 | date = February 2018 | pmid = 29467203 | pmc = 5886843 | doi = 10.1183/13993003.01815-2017 }}
133. ^{{cite journal | vauthors = Karakantza M, Matutes E, MacLennan K, O'Connor NT, Srivastava PC, Catovsky D | title = Association between sarcoidosis and lymphoma revisited | journal = Journal of Clinical Pathology | volume = 49 | issue = 3 | pages = 208–12 | date = March 1996 | pmid = 8675730 | pmc = 500399 | doi = 10.1136/jcp.49.3.208 }}
134. ^{{cite journal | vauthors = Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A | title = Increased risk for cancer following sarcoidosis | journal = American Journal of Respiratory and Critical Care Medicine | volume = 160 | issue = 5 Pt 1 | pages = 1668–72 | date = November 1999 | pmid = 10556138 | doi = 10.1164/ajrccm.160.5.9904045 }}
135. ^{{cite journal | vauthors = Tana C, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C | title = Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? | journal = International Journal of Immunopathology and Pharmacology | volume = 26 | issue = 2 | pages = 305–13 | date = April–June 2013 | pmid = 23755746 | doi = 10.1177/039463201302600204 }}
136. ^{{cite journal | vauthors = Kornacker M, Kraemer A, Leo E, Ho AD | title = Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases | journal = Annals of Hematology | volume = 81 | issue = 2 | pages = 103–5 | date = February 2002 | pmid = 11907791 | doi = 10.1007/s00277-001-0415-6 }}
137. ^{{cite journal | vauthors = Suvajdzic N, Milenkovic B, Perunicic M, Stojsic J, Jankovic S | title = Two cases of sarcoidosis-lymphoma syndrome | journal = Medical Oncology | volume = 24 | issue = 4 | pages = 469–71 | year = 2007 | pmid = 17917102 | doi = 10.1007/s12032-007-0026-8 }}
138. ^{{cite journal | vauthors = London J, Grados A, Fermé C, Charmillon A, Maurier F, Deau B, Crickx E, Brice P, Chapelon-Abric C, Haioun C, Burroni B, Alifano M, Le Jeunne C, Guillevin L, Costedoat-Chalumeau N, Schleinitz N, Mouthon L, Terrier B | title = Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature | journal = Medicine | volume = 93 | issue = 21 | pages = e121 | date = November 2014 | pmid = 25380084 | pmc = 4616278 | doi = 10.1097/MD.0000000000000121 }}
139. ^{{cite journal | vauthors = Yao M, Funk GF, Goldstein DP, DeYoung BR, Graham MM | title = Benign lesions in cancer patients: Case 1. Sarcoidosis after chemoradiation for head and neck cancer | journal = Journal of Clinical Oncology | volume = 23 | issue = 3 | pages = 640–1 | date = January 2005 | pmid = 15659510 | doi = 10.1200/JCO.2005.02.089 }}
140. ^{{cite journal | vauthors = Yamasawa H, Ishii Y, Kitamura S | title = Concurrence of sarcoidosis and lung cancer. A report of four cases | journal = Respiration; International Review of Thoracic Diseases | volume = 67 | issue = 1 | pages = 90–3 | year = 2000 | pmid = 10705270 | doi = 10.1159/000029470 }}
141. ^{{cite journal | vauthors = Zambrana F, Antúnez A, García-Mata J, Mellado JM, Villar JL | title = Sarcoidosis as a diagnostic pitfall of pancreatic cancer | journal = Clinical & Translational Oncology | volume = 11 | issue = 6 | pages = 396–8 | date = June 2009 | pmid = 19531456 | doi = 10.1007/s12094-009-0375-1 }}
142. ^{{cite journal | vauthors = Schiller G, Said J, Pal S | title = Hairy cell leukemia and sarcoidosis: a case report and review of the literature | journal = Leukemia | volume = 17 | issue = 10 | pages = 2057–9 | date = October 2003 | pmid = 14513061 | doi = 10.1038/sj.leu.2403074 }}
143. ^{{cite journal | vauthors = Maloisel F, Oberling F | title = Acute myeloid leukemia complicating sarcoidosis | journal = Journal of the Royal Society of Medicine | volume = 85 | issue = 1 | pages = 58–9 | date = January 1992 | pmid = 1548666 | pmc = 1293471 | doi = }}
144. ^{{cite journal | vauthors = Reich JM | title = Acute myeloblastic leukemia and sarcoidosis. Implications for pathogenesis | journal = Cancer | volume = 55 | issue = 2 | pages = 366–9 | date = January 1985 | pmid = 3855267 | doi = 10.1002/1097-0142(19850115)55:2<366::AID-CNCR2820550212>3.0.CO;2-1 }}
145. ^{{cite journal | vauthors = Jamilloux Y, Valeyre D, Lortholary O, Bernard C, Kerever S, Lelievre L, Neel A, Broussolle C, Seve P | title = The spectrum of opportunistic diseases complicating sarcoidosis | journal = Autoimmunity Reviews | volume = 14 | issue = 1 | pages = 64–74 | date = January 2015 | pmid = 25305373 | doi = 10.1016/j.autrev.2014.10.006 }}
146. ^{{cite journal | vauthors = Jamilloux Y, Néel A, Lecouffe-Desprets M, Fèvre A, Kerever S, Guillon B, Bouvry D, Varron L, Redares C, Dominique S, Roux M, Chapelon-Abric C, Valeyre D, Ducray F, Bernard C, Broussolle C, Hamidou M, Sève P | title = Progressive multifocal leukoencephalopathy in patients with sarcoidosis | journal = Neurology | volume = 82 | issue = 15 | pages = 1307–13 | date = April 2014 | pmid = 24610328 | doi = 10.1212/WNL.0000000000000318 }}
147. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 {{cite journal | vauthors = Nunes H, Bouvry D, Soler P, Valeyre D | title = Sarcoidosis | journal = Orphanet Journal of Rare Diseases | volume = 2 | pages = 46 | date = November 2007 | pmid = 18021432 | pmc = 2169207 | doi = 10.1186/1750-1172-2-46 }}
148. ^{{cite book |last= Sam |first= Amir H. |author2=James T.H. Teo |title= Rapid Medicine |publisher= Wiley-Blackwell |year= 2010 |isbn= 978-1405183239}}
149. ^{{cite journal | vauthors = Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT | title = The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival | journal = American Journal of Epidemiology | volume = 123 | issue = 5 | pages = 840–5 | date = May 1986 | pmid = 3962966 | doi = 10.1093/oxfordjournals.aje.a114313| url = http://aje.oxfordjournals.org/content/123/5/840.full.pdf }}
150. ^{{cite journal | vauthors = Rutherford RM, Brutsche MH, Kearns M, Bourke M, Stevens F, Gilmartin JJ | title = Prevalence of coeliac disease in patients with sarcoidosis | journal = European Journal of Gastroenterology & Hepatology | volume = 16 | issue = 9 | pages = 911–5 | date = September 2004 | pmid = 15316417 | doi = 10.1097/00042737-200409000-00016 | url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0954-691X&volume=16&issue=9&spage=911 }}
151. ^1 {{cite journal | vauthors = Baughman RP, Lower EE, du Bois RM | title = Sarcoidosis | journal = Lancet | volume = 361 | issue = 9363 | pages = 1111–8 | date = March 2003 | pmid = 12672326 | doi = 10.1016/S0140-6736(03)12888-7 }}
152. ^1 {{cite journal | vauthors = Lazarus A | title = Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics | journal = Disease-A-Month | volume = 55 | issue = 11 | pages = 649–60 | date = November 2009 | pmid = 19857640 | doi = 10.1016/j.disamonth.2009.04.008 }}
153. ^1 2 3 4 5 6 {{cite book|last=Sharma|first=OP|title=Sarcoidosis.|year=2005|publisher=European Respiratory Society Journals|location=Sheffield|isbn=9781904097884|chapter=Chapter 1: Definition and history of sarcoidosis}}
154. ^{{cite journal|last=Babalian|first=L|title=Disease of Besnier-Boeck-Schaumann|journal=New England Journal of Medicine|date=26 January 1939|volume=220|issue=4|pages=143–145|doi=10.1056/NEJM193901262200404}}
155. ^{{cite web |title= Join WASOG |work= wasog.org |agency= World Association of Sarcoidosis and Other Granulomatous Disorders |access-date= 21 February 2014 |url= http://www.wasog.org/ |deadurl= no |archive-url= https://web.archive.org/web/20140201104159/http://www.wasog.org/ |archive-date= 1 February 2014 |df= }}
156. ^{{cite journal |journal= Sarcoidosis, Vasculitis and Diffuse Lung Diseases |title= Index |date= 2016 |url= http://www.mattioli1885journals.com/index.php/sarcoidosis/index |access-date= 9 April 2016 |deadurl= no |archive-url= https://web.archive.org/web/20160506192503/http://www.mattioli1885journals.com/index.php/sarcoidosis/index |archive-date= 6 May 2016 |df= }}
157. ^{{cite web|title=Mission & Goals|work=Foundation for Sarcoidosis Research|access-date=21 February 2014|url=http://www.stopsarcoidosis.org/about-us/mission_goals/|deadurl=no|archive-url=https://web.archive.org/web/20140226185057/http://www.stopsarcoidosis.org/about-us/mission_goals/|archive-date=26 February 2014|df=}}
158. ^{{cite journal | vauthors = Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, Hall C, Kelly KJ, Prezant DJ | title = World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York City Fire Department rescue workers | journal = Chest | volume = 131 | issue = 5 | pages = 1414–23 | date = May 2007 | pmid = 17400664 | doi = 10.1378/chest.06-2114 | url = http://journal.publications.chestnet.org/data/Journals/CHEST/22056/1414.pdf }}
159. ^{{cite web|title=9/11 Health – What We Know About the Health Effects of 9/11|work=NYC|publisher=US Government|access-date=22 February 2014|url=http://www.nyc.gov/html/doh/wtc/html/know/physical.shtml|deadurl=no|archive-url=https://web.archive.org/web/20140128020514/http://www.nyc.gov/html/doh/wtc/html/know/physical.shtml|archive-date=28 January 2014|df=}}
160. ^{{cite news|last=Grimes|first=William|title=Bernie Mac, Acerbic Stand-Up Comedian and Irascible TV Dad, Dies at 50|url=https://www.nytimes.com/2008/08/10/arts/television/10mac.html|access-date=30 April 2014|newspaper=The New York Times|date=10 August 2008|deadurl=no|archive-url=https://web.archive.org/web/20140314170207/http://www.nytimes.com/2008/08/10/arts/television/10mac.html|archive-date=14 March 2014|df=}}
161. ^{{cite journal | vauthors = Charlier P, Froesch P | title = Robespierre: the oldest case of sarcoidosis? | journal = Lancet | volume = 382 | issue = 9910 | pages = 2068 | date = December 2013 | pmid = 24360387 | doi = 10.1016/S0140-6736(13)62694-X }}
162. ^{{cite journal | vauthors = Subramanian P, Chinthalapalli H, Krishnan M, Tarlo SM, Lobbedez T, Pineda ME, Oreopoulos DG | title = Pregnancy and sarcoidosis: an insight into the pathogenesis of hypercalciuria | journal = Chest | volume = 126 | issue = 3 | pages = 995–8 | date = September 2004 | pmid = 15364785 | doi = 10.1378/chest.126.3.995 }}

External links

{{Medical condition classification and resources
| DiseasesDB = 11797
| ICD10 = {{ICD10|D|86||d|80}}
| ICD9 = {{ICD9|135}}
| ICDO =
| OMIM = 181000
| MedlinePlus = 000076
| eMedicineSubj = med
| eMedicineTopic = 2063
| MeshID = D012507
}}
  • {{cite book |author=Iannuzzi, M. C.; Sah, B. P. |date=March 2008 |title=Sarcoidosis: Interstitial Lung Diseases |url=http://www.merckmanuals.com/home/lung_and_airway_disorders/interstitial_lung_diseases/sarcoidosis.html |work= The Merck Manual Home Edition |publisher= Merck Sharp & Dohme Corp |access-date= 19 February 2014}}
{{Sarcoidosis}}{{Arthritis in children}}{{Authority control}}

8 : Ailments of unknown cause|Lung disorders|Abdominal pain|Monocyte- and macrophage-related cutaneous conditions|Autoimmune diseases|RTT|Steroid-responsive inflammatory conditions|RTTNEURO
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/13 11:21:31